Regeneus, a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.
- Sygenus topical gel improves the appearance of acne in adults
- Sygenus gel was well tolerated when applied twice daily for 6 weeks
- Significant reduction seen in the appearance of non-inflammatory lesions such as blackheads and whiteheads, and inflammatory papules
- Significant reduction noted in acne global severity score at 6 weeks
Sygenus is a patented allogeneic cell secretions technology platform that comprises cytokines, growth factors and exosomes from adipose-derived mesenchymal stem cells (MSCs). These bioactive molecules work to reduce pain and inflammation and encourage accelerated healing and repair.
The tolerance study, performed by RCTS, a dermatology testing company in Texas, aimed to look at the tolerability of Sygenus in 33 healthy volunteers with mild to moderate facial acne. The study endpoints to assess tolerability involved the change in acne lesions over the 6-week period. Sygenus gel was applied topically twice a day throughout the study. No intolerance was observed and there was an overall improvement in the appearance of acne, as early as 3 weeks. Statistically significant reductions in the total number of inflammatory and non-inflammatory acne lesions were noted from baseline to week 6. Further the acne global severity score showed significant reduction (improvement) at week 6 compared to baseline.
These promising results will help in the partnering of Sygenus gel for the acne market and other inflammatory skin conditions. With few treatment innovations or improvements without significant side effects in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high.
Regeneus has received granted patents in Australia, Europe, China, USA and Japan covering the composition, manufacture and use of the Sygenus technology for the topical treatment of acne. The company also has patent applications for the use of Sygenus for a broad range of other inflammatory skin conditions.
More about Sygenus
Sygenus is a patented allogeneic cell secretions technology platform that utilises the molecules (including cytokines, growth factors and exosomes) that are secreted by donor adipose-derived MSCs and work to reduce pain and inflammation and encourage accelerated healing and repair. Regeneus has developed technology and intellectual property for the scalable production of secretions of MSCs which have the potential to be used as an off-the-shelf treatment for multiple indications and in a range of delivery methods.
Source – ABN Newwire